Cargando…
Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution
Caplacizumab prevents platelet adhesion and has been approved for acquired thrombotic thrombocytopenic purpura (aTTP). This study was retrospective, including all patients diagnosed with aTTP and treated with caplacizumab since commercial availability in 2019 until 28 February 2021 at a single acade...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347784/ https://www.ncbi.nlm.nih.gov/pubmed/34362201 http://dx.doi.org/10.3390/jcm10153418 |
_version_ | 1783735178455154688 |
---|---|
author | Logothetis, Constantine N. Patel, Ankita Eatrides, Jennifer Jaglal, Michael Haider, Mintallah Visweshwar, Nathan Laber, Damian A. |
author_facet | Logothetis, Constantine N. Patel, Ankita Eatrides, Jennifer Jaglal, Michael Haider, Mintallah Visweshwar, Nathan Laber, Damian A. |
author_sort | Logothetis, Constantine N. |
collection | PubMed |
description | Caplacizumab prevents platelet adhesion and has been approved for acquired thrombotic thrombocytopenic purpura (aTTP). This study was retrospective, including all patients diagnosed with aTTP and treated with caplacizumab since commercial availability in 2019 until 28 February 2021 at a single academic hospital with no exclusion criteria. Results used definitions for outcomes in aTTP from the International Working Group Consensus. Ten patients with aTTP received caplacizumab. The median age was 52 years. Six (60%) patients had refractory aTTP while 4 (40%) had newly diagnosed aTTP. The median laboratory values prior to therapy demonstrated: platelet count (PC) 29/uL, LDH 518 U/L (182–1850), ADAMTS13 activity 3% and ADAMTS13 inhibitor 1.4 BU. Everyone received glucocorticoids, rituximab, therapeutic plasma exchange (TPE) and caplacizumab. The median number of TPE was 12 days. Caplacizumab was started at a median of 5 days after the first TPE and the median treatment duration was 31 days. Normalization of PC, LDH and ADAMTS13 activity in days were 5, 3.5, and 32.5, respectively. Six (60%) patients achieved complete response, 3 (30%) had refractory disease and 1 (10%) had relapsed aTTP. No subject suffered abnormal bleeding, or thrombotic event. There were no deaths. Caplacizumab with TPE, glucocorticoids and rituximab was a safe and effective therapy for aTTP. |
format | Online Article Text |
id | pubmed-8347784 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83477842021-08-08 Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution Logothetis, Constantine N. Patel, Ankita Eatrides, Jennifer Jaglal, Michael Haider, Mintallah Visweshwar, Nathan Laber, Damian A. J Clin Med Article Caplacizumab prevents platelet adhesion and has been approved for acquired thrombotic thrombocytopenic purpura (aTTP). This study was retrospective, including all patients diagnosed with aTTP and treated with caplacizumab since commercial availability in 2019 until 28 February 2021 at a single academic hospital with no exclusion criteria. Results used definitions for outcomes in aTTP from the International Working Group Consensus. Ten patients with aTTP received caplacizumab. The median age was 52 years. Six (60%) patients had refractory aTTP while 4 (40%) had newly diagnosed aTTP. The median laboratory values prior to therapy demonstrated: platelet count (PC) 29/uL, LDH 518 U/L (182–1850), ADAMTS13 activity 3% and ADAMTS13 inhibitor 1.4 BU. Everyone received glucocorticoids, rituximab, therapeutic plasma exchange (TPE) and caplacizumab. The median number of TPE was 12 days. Caplacizumab was started at a median of 5 days after the first TPE and the median treatment duration was 31 days. Normalization of PC, LDH and ADAMTS13 activity in days were 5, 3.5, and 32.5, respectively. Six (60%) patients achieved complete response, 3 (30%) had refractory disease and 1 (10%) had relapsed aTTP. No subject suffered abnormal bleeding, or thrombotic event. There were no deaths. Caplacizumab with TPE, glucocorticoids and rituximab was a safe and effective therapy for aTTP. MDPI 2021-07-31 /pmc/articles/PMC8347784/ /pubmed/34362201 http://dx.doi.org/10.3390/jcm10153418 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Logothetis, Constantine N. Patel, Ankita Eatrides, Jennifer Jaglal, Michael Haider, Mintallah Visweshwar, Nathan Laber, Damian A. Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution |
title | Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution |
title_full | Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution |
title_fullStr | Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution |
title_full_unstemmed | Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution |
title_short | Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution |
title_sort | post approval experience with caplacizumab for acquired thrombotic thrombocytopenic purpura at a single institution |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347784/ https://www.ncbi.nlm.nih.gov/pubmed/34362201 http://dx.doi.org/10.3390/jcm10153418 |
work_keys_str_mv | AT logothetisconstantinen postapprovalexperiencewithcaplacizumabforacquiredthromboticthrombocytopenicpurpuraatasingleinstitution AT patelankita postapprovalexperiencewithcaplacizumabforacquiredthromboticthrombocytopenicpurpuraatasingleinstitution AT eatridesjennifer postapprovalexperiencewithcaplacizumabforacquiredthromboticthrombocytopenicpurpuraatasingleinstitution AT jaglalmichael postapprovalexperiencewithcaplacizumabforacquiredthromboticthrombocytopenicpurpuraatasingleinstitution AT haidermintallah postapprovalexperiencewithcaplacizumabforacquiredthromboticthrombocytopenicpurpuraatasingleinstitution AT visweshwarnathan postapprovalexperiencewithcaplacizumabforacquiredthromboticthrombocytopenicpurpuraatasingleinstitution AT laberdamiana postapprovalexperiencewithcaplacizumabforacquiredthromboticthrombocytopenicpurpuraatasingleinstitution |